Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
Primary Objective:
To investigate the value of the Edinburgh Claudication Questionnaire (ECQ) against the ankle-brachial index (ABI) in Canadian patients mainly followed in general practice, with documented acute coronary syndrome (ACS)/ischemic stroke (IS)/transient ischemic attack (TIA) and who are not known to have peripheral arterial disease (PAD) at the time of enrolment.
Secondary Objective:
To collect data on the prevalence of PAD in this population as measured by ABI.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| single group study |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To determine the sensitivity and specificity of the ECQ versus ABI. | within 12 (+/- 2) weeks |
| Measure | Description | Time Frame |
|---|---|---|
| To determine the prevalence of symptomatic PAD (positive ECQ and ABIT <0.9) | within 12 (+/- 2) weeks | |
| To determine the prevalence of asymptomatic PAD (negative ECQ and ABI <0.9) | within 12 (+/- 2) weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Previously known symptomatic or asymptomatic PAD confirmed by one of the following diagnostic methods or interventions (documented in the patient's medical record):
Patients whose ABI cannot be measured accurately
Patients already in a clinical trial or a product registry
Hospitalized patients
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Not provided
Not provided
Not provided
Patients with documented ACS or/and IS / TIA
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Affairs | Sanofi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sanofi-Aventis Administrative Office | Laval | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23692499 | Derived | Bell AD, Roussin A, Popovici-Toma D, Girard M, Chiu JF, Huckell V. The value of routine screening for peripheral arterial disease in stable outpatients with a history of coronary artery or cerebrovascular disease. Int J Clin Pract. 2013 Oct;67(10):996-1004. doi: 10.1111/ijcp.12148. Epub 2013 May 21. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016491 | Peripheral Vascular Diseases |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided